Global Leading Market Research Publisher QYResearch announces the release of its latest report "Volume Expander - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Volume Expander market, including market size, share, demand, industry development status, and forecasts for the next few years. For clinicians, emergency medicine physicians, anesthesiologists, and hospital procurement directors, managing acute blood loss from trauma, hemorrhage, surgery, or severe dehydration presents a critical time-sensitive challenge. Hypovolemia (low blood volume) leads to decreased blood pressure, reduced organ perfusion, and ultimately shock, organ failure, and death if not rapidly corrected. Volume expanders are intravenous medical solutions used to increase blood volume in cases of hypovolemia, working by retaining fluid in the bloodstream, improving circulation, and preventing shock. Common types include crystalloids (e.g., saline solution, Ringer's lactate) and colloids (e.g., albumin, dextran, hydroxyethyl starch). These solutions help restore blood pressure and maintain organ perfusion during fluid loss, serving as essential tools in emergency departments, operating rooms, intensive care units, and trauma centers. The global market for Volume Expander was estimated to be worth USD 225 million in 2024 and is forecast to reach a readjusted size of USD 326 million by 2031, growing at a CAGR of 5.9% during the forecast period 2025-2031. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/4667789/volume-expander 1. Product Definition and Core Technology Types A volume expander is a type of intravenous medical solution used to increase blood volume in cases of hypovolemia (low blood volume) resulting from hemorrhage, dehydration, burns, or surgery. These solutions are administered intravenously to restore circulating blood volume, maintain blood pressure, and preserve organ perfusion during acute fluid loss. Core Product Segments: Human Albumin (approximately 35-40% of market value): The largest and most premium segment. Human albumin is a natural colloid derived from human plasma (pooled, fractionated, and purified). Albumin solutions (typically 5% or 25% concentration) are used for volume expansion in hypovolemic shock, burns, hypoalbuminemia (low albumin levels from liver disease, malnutrition, nephrotic syndrome), and cardiopulmonary bypass surgery. Advantages: natural protein with oncotic pressure identical to plasma, low risk of allergic reaction (human-derived), and long intravascular retention (12-24 hours). Disadvantages: high cost (USD 50-200 per 100ml), plasma supply constraints (requires donor plasma fractionation), and theoretical risk of pathogen transmission (though screening and viral inactivation minimize risk). Key players: CSL Behring, Kedrion Biopharma, Takeda Pharmaceuticals, Grifols, Octapharma. Colloids (synthetic, approximately 25-30% of market value): Synthetic volume expanders including hydroxyethyl starch (HES, Hespan, Voluven), dextran (Gentran, LMD), and gelatin (Gelofusine, Haemaccel). Advantages: longer intravascular retention than crystalloids, lower cost than albumin (USD 20-60 per 500ml), and no plasma supply constraints (synthetic production). Disadvantages: risk of coagulopathy (bleeding) with HES (limiting use in septic patients, renal impairment), risk of anaphylaxis (dextran, gelatin), and renal toxicity concerns. HES use has declined following safety warnings (FDA boxed warning for sepsis, burns, critical illness; European Medicines Agency restrictions). Key players: Fresenius Kabi (Voluven, HES), B. Braun, Pfizer (Hespan), Piramal Critical Care, Pentagon Labs. Hydroxyethyl Starch (HES) (approximately 15-20% of market value, declining): A specific type of synthetic colloid, but declining due to safety concerns. HES market share has decreased from 25-30% in 2015 to 15-20% in 2024 following regulatory restrictions. Some markets still use HES for intraoperative volume replacement in surgical patients without sepsis or renal impairment. Plasma Protein Fraction (PPF, approximately 5-10% of market value): A plasma-derived colloid containing albumin and other plasma proteins (alpha and beta globulins). Similar indications to albumin but less purified and lower cost. PPF has lost market share to recombinant and more purified albumin products. Dextran (approximately 5-10% of market value, stable niche): A synthetic colloid (branched polysaccharide) used for volume expansion and prophylaxis of venous thromboembolism (VTE) in high-risk surgical patients. Dextran has higher anaphylaxis risk than other colloids, limiting use to specific indications. Crystalloids (saline, Ringer's lactate, balanced solutions): Not included in this market segmentation (market scope focuses on colloid volume expanders). Crystalloids are significantly lower cost (USD 1-5 per liter) but have shorter intravascular retention, requiring larger volumes for equivalent expansion. Application Segmentation: Hospitals (approximately 60-70% of market value): The largest segment, including emergency departments (trauma, hemorrhage, sepsis), operating rooms (surgical blood loss, intraoperative fluid management), intensive care units (ICU, critical illness, burns), and general wards (dehydration, hypovolemia from medical conditions). Hospitals require volume expanders in multiple sizes (250ml, 500ml, 1000ml) with extended shelf life and compatibility with standard IV administration sets. Clinics (approximately 15-20% of market value): Ambulatory surgical centers, urgent care centers, and large outpatient clinics performing procedures with risk of fluid loss. Clinic usage is lower volume per facility but serves as additional distribution channel. Other (approximately 10-15% of market value): Ambulance services and emergency medical services (EMS, pre-hospital fluid resuscitation), military medical facilities (combat casualty care), and home infusion services. 2. Market Size Trajectory and Key Growth Drivers The volume expander market, as tracked by QYResearch, shows steady growth from USD 225 million in 2024 to USD 326 million by 2031, representing a 5.9% CAGR. Driver 1: Growing Surgical Procedures and Trauma Cases: The increasing number of surgeries (e.g., cardiovascular, orthopedic, gastrointestinal, trauma) and emergency interventions globally drives demand for volume expanders like crystalloids and colloids. Global surgical volume is estimated at 300-350 million procedures annually (pre-pandemic), with growth of 3-5% annually. Each major surgery (cardiovascular, orthopedic, abdominal) may require 500-2000ml of volume expander for intraoperative fluid management. Trauma cases (road traffic accidents, falls, violence) require emergency volume resuscitation. Emerging economies, such as India and China, are witnessing rapid healthcare infrastructure development (new hospitals, trauma centers, surgical capacity), further boosting adoption. Driver 2: Aging Population and Chronic Diseases: Aging populations in regions such as North America, Europe, and Asia-Pacific are prone to chronic conditions (e.g., diabetes, cardiovascular disease, renal disorders, liver disease), necessitating fluid management solutions. Patients with chronic diseases are more likely to require surgery (higher surgical volume) and experience complications requiring volume resuscitation (sepsis, dehydration, bleeding). The global population aged 65+ is projected to reach 1.5 billion by 2050 (from 1 billion in 2020), creating sustained demand for volume expanders in hospitals and clinics. Driver 3: Expansion in Emerging Markets: Asia-Pacific, particularly China and India, offers untapped potential due to rising healthcare expenditure and government initiatives to improve critical care access. China's healthcare reform (Healthy China 2030) includes expansion of hospital capacity, emergency services, and critical care infrastructure. India's Ayushman Bharat scheme (largest government-funded healthcare program) increases access to hospital care. Local production of cost-effective volume expanders (including plasma-derived albumin from domestic fractionation) could dominate these markets. Chinese manufacturers (Huaren Pharmaceutical, Kelun Pharmacy, China Res Double-Crane) are gaining domestic market share with lower-priced products (20-30% below international brands). Driver 4: Post-Pandemic Recovery and Supply Chain Resilience: Post-COVID-19, healthcare systems prioritize stockpiling essential fluids and maintaining buffer inventories. The pandemic exposed supply chain vulnerabilities (plasma collection disruptions, import/export restrictions, transportation delays). Manufacturers are diversifying supply chains (multiple raw material sources, regional production facilities) to mitigate disruptions, as seen in the polymer emulsion market's recovery strategies. Hospitals are increasing inventory levels (safety stock) of critical volume expanders, supporting near-term demand. Exclusive Observation – Human Albumin Dominance and Plasma Supply Constraints: Human albumin (35-40% share) is the premium volume expander segment, but its growth is constrained by plasma supply (source plasma collected from donors). Plasma collection declined during COVID-19 (lockdowns, donor deferrals) and has not fully recovered. Plasma collection economics (donor compensation, collection center costs) favor high-income countries (US, Germany, Austria, Hungary). Manufacturers with integrated plasma collection networks (CSL Behring, Takeda, Kedrion) have competitive advantage over manufacturers purchasing plasma on the open market. The market research indicates that human albumin market share will remain stable (35-40%) rather than increasing, constrained by plasma supply. 3. Industry Development Characteristics and Competitive Landscape As a senior industry analyst, I observe several defining characteristics that differentiate the volume expander market. Characteristic 1 – Concentrated Market with Plasma-Derived and Synthetic Players: The volume expander market is concentrated, with the top 5 players (B. Braun, Fresenius Kabi, Pfizer, CSL Behring, Takeda) holding approximately 60-65% of global market share. Tier Key Players Market Characteristics Global Leaders (Plasma + Synthetic) CSL Behring, Takeda, Kedrion (plasma-derived albumin, PPF); B. Braun, Fresenius Kabi, Pfizer (synthetic colloids, HES, dextran) Broad product portfolios, global distribution, strong hospital relationships Regional/National Piramal Critical Care (India), Pentagon Labs (India), Huaren Pharmaceutical (China), Kelun Pharmacy (China), China Res Double-Crane (China), Rusoma (Russia) Lower pricing, domestic market focus, regulatory relationships Characteristic 2 – Geographic Concentration in Plasma Collection: Plasma-derived albumin production is concentrated in North America (US), Europe (Germany, Austria, Hungary, Czech Republic), and increasingly China (domestic fractionation). The US is the largest plasma collection market globally (approximately 70% of source plasma), due to donor compensation (paid donation permitted) and established collection infrastructure (plasma collection centers). This geographic concentration creates supply chain vulnerability for non-US manufacturers. Characteristic 3 – Regulatory Differences Across Markets: HES (hydroxyethyl starch) is restricted or contraindicated in many markets. FDA boxed warning (2013): HES not indicated for sepsis, burns, critical illness; use only for intraoperative volume replacement in surgical patients. European Medicines Agency (EMA) contraindication (2018): HES not for use in septic patients, burns, critical illness; restricted to intraoperative use with specific labeling. Chinese and Indian regulators have not implemented similar restrictions, allowing continued HES use in broader indications, creating regional market differences. Characteristic 4 – Hospital Segment Dominance: Hospitals (60-70% share) dominate because volume expanders are administered in acute care settings (emergency, operating room, ICU) where patient monitoring is available. Clinics and other settings are smaller, serving lower-acuity patients. This hospital concentration means manufacturers must maintain sales forces and distribution relationships with hospital pharmacy directors, anesthesiologists, and emergency medicine physicians. Exclusive Observation – Innovation in Formulations and Safety: Companies are investing in low-VOC and biocompatible formulations to meet stringent regulatory standards. For example, BASF's ultra-low-VOC polymer emulsions highlight trends in safer medical-grade materials, which could inspire similar advancements in intravenous solutions. However, volume expander formulation innovation is limited compared to other medical device or pharmaceutical categories, because safety concerns (anaphylaxis, coagulopathy, renal toxicity) have driven regulatory restrictions (HES) rather than product improvements. Future formulation innovation may focus on biocompatible synthetic colloids with improved safety profiles (reduced anaphylaxis risk, no coagulopathy, no renal toxicity) to replace HES and compete with albumin. 4. Recent User Cases and Market Developments (2025-2026) User Case – Trauma Center Volume Resuscitation Protocol: A Level 1 trauma center in the United States updated its massive transfusion protocol (MTP) in 2025 to prioritize balanced resuscitation (crystalloids + colloids + blood products) for hemorrhagic shock patients. The protocol specifies human albumin (5%) for volume expansion after initial crystalloid resuscitation, reserving synthetic colloids (HES) only for operating room use in non-septic, non-renal impairment patients. The updated protocol reduced crystalloid volume administered (reducing dilutional coagulopathy, edema) and improved 24-hour survival in hemorrhagic shock patients (82% vs. 74% prior). Albumin utilization at the center increased 40% year-over-year. User Case – Chinese Domestic Albumin Production Expansion: China's National Medical Products Administration (NMPA) approved two new domestic plasma fractionation facilities in 2025 (Huaren Pharmaceutical, Kelun Pharmacy), increasing domestic human albumin production capacity by an estimated 30%. China previously relied on imported albumin (CSL Behring, Takeda, Kedrion, Grifols) for 60-70% of consumption. Domestic production at lower cost (20-30% below imported brands) enables Chinese hospitals to expand albumin use for volume expansion (previously limited by cost in some regions) and reduces supply chain dependence. Exclusive Observation – HES Market Decline Continues: The market research indicates HES market share will continue declining (from 15-20% in 2024 to 10-15% by 2031) as regulatory restrictions remain in place and hospitals shift to albumin (preferred colloid) or crystalloids (lower cost, though shorter duration). HES use persists in surgical settings (intraoperative) where coagulopathy risk is monitored and renal function is normal, but albumin is increasingly preferred for septic patients and critical illness. Manufacturers have diversified into other hospital fluid products (IV solutions, irrigation fluids, parenteral nutrition) to offset HES revenue decline. 5. Technical Challenges and Future Outlook (2026-2032) Technical Challenge – Hypersensitivity and Anaphylaxis Risk: Dextran and gelatin synthetic colloids carry risk of anaphylaxis (severe allergic reaction) ranging from 0.1-1% of administrations, requiring availability of emergency treatment (epinephrine, antihistamines) when administering. Albumin (human-derived) and HES have lower anaphylaxis risk (0.01-0.1%). Risk management requires hospital protocols and staff training. Technical Challenge – Plasma Supply and Cost: Human albumin production requires source plasma (donated or paid collection). Plasma collection costs have increased (donor compensation, collection center operations, testing, storage). Plasma shortages periodically occur (post-pandemic, seasonal). Albumin pricing has increased 3-5% annually over the past five years, while synthetic colloid pricing has remained stable or declined. This price divergence may shift some price-sensitive markets (emerging economies) toward synthetic colloids or crystalloids, despite safety concerns. Future Industry Directions (2026-2030): Recombinant Human Albumin: Recombinant production (via yeast or plant expression systems) could eliminate plasma dependence and reduce cost. Recombinant albumin development has faced technical challenges (yield, purity, post-translational modifications, regulatory approval). Several companies have research programs; commercial availability unlikely before 2028-2030. Next-Generation Synthetic Colloids: Biocompatible synthetic colloids with improved safety profile (no coagulopathy, no anaphylaxis, no renal toxicity) are in early research. Reduced cross-linking HES derivatives, PEGylated colloids, and other novel polymers are under investigation. Clinical trials expected 2026-2028. Expansion in Emerging Markets: Asia-Pacific (China, India, Indonesia, Vietnam, Philippines) and Latin America (Brazil, Mexico, Argentina) offer growth opportunities as healthcare infrastructure expands (new hospitals, trauma centers, surgical capacity). Local manufacturers (Huaren Pharmaceutical, Kelun Pharmacy, China Res Double-Crane in China; Piramal Critical Care, Pentagon Labs in India) are gaining share through lower pricing, regulatory relationships, and domestic distribution. Exclusive Forecast Observation – Market Growth by Region: The market research indicates that Asia-Pacific will be the fastest-growing regional market (7-8% CAGR), driven by China (domestic albumin production expansion, hospital infrastructure investment) and India (Ayushman Bharat scheme increasing hospital access, rising trauma and surgical volume). North America and Europe will grow at 3-5% CAGR (mature markets, stable demand). Latin America and Middle East/Africa will grow at 4-6% CAGR (gradual infrastructure improvement). 6. Conclusion – Steady Growth in Critical Care Fluid Resuscitation The Volume Expander market is positioned for steady growth from USD 225 million to USD 326 million at a 5.9% CAGR through 2031, driven by surgical procedure growth, trauma and emergency care demand, aging populations, and emerging market healthcare infrastructure expansion. Human albumin (35-40% share) dominates the premium segment, with synthetic colloids (HES, dextran, other) comprising the remainder. Hospitals are the largest application segment (60-70% share). CSL Behring, Takeda, B. Braun, Fresenius Kabi, and Pfizer lead the concentrated market. For manufacturers, key strategic priorities include plasma supply chain security (for albumin producers), emerging market expansion (China, India, Southeast Asia), regulatory compliance (HES restrictions vary by region), and synthetic colloid safety innovation (next-generation products with improved profiles). For investors, the volume expander market offers stable, defensible growth with essential acute care products and barriers to entry (plasma infrastructure, regulatory approvals, hospital relationships). For detailed competitive benchmarking, regional adoption analysis, product type forecasts (human albumin, colloids, HES, plasma protein fraction, dextran), application analysis (hospitals, clinics, other), and 36-month rolling projections across 8 major regions, the full QYResearch report provides actionable intelligence for strategic planning and investment decision-making. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp